Compare · AXGN vs ELMD
AXGN vs ELMD
Side-by-side comparison of Axogen Inc. (AXGN) and Electromed Inc. (ELMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AXGN and ELMD operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- AXGN is the larger of the two at $2.25B, about 10.1x ELMD ($223.0M).
- Over the past year, AXGN is up 149.0% and ELMD is up 7.3% - AXGN leads by 141.7 points.
- AXGN has been more active in the news (8 items in the past 4 weeks vs 7 for ELMD).
- AXGN has more recent analyst coverage (9 ratings vs 3 for ELMD).
- Company
- Axogen Inc.
- Electromed Inc.
- Price
- $41.85-11.31%
- $26.76-1.11%
- Market cap
- $2.25B
- $223.0M
- 1M return
- -13.75%
- -36.90%
- 1Y return
- +149.03%
- +7.34%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- AMEX
- IPO
- 2011
- News (4w)
- 8
- 7
- Recent ratings
- 9
- 3
Axogen Inc.
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
Electromed Inc.
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system; SmartVest SQL System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment; and SmartVest Connect, a wireless technology with personalized HFCWO therapy management portal for patients with compromised pulmonary function. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products primarily to home health care market for patients with bronchiectasis, cystic fibrosis, and neuromuscular disease. Electromed, Inc. markets its products primarily to physicians and health care providers, as well as directly to patients. The company was incorporated in 1992 and is headquartered in New Prague, Minnesota.
Latest AXGN
- SEC Form 424B5 filed by Axogen Inc.
- Amendment: Axogen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Axogen Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock
- Axogen Enters into Definitive Agreement to Acquire BioCircuit Technologies
- Director Tyndall Joseph A. sold $173,940 worth of shares (3,500 units at $49.70) as part of a pre-agreed trading plan, decreasing direct ownership by 25% to 10,650 units (SEC Form 4)
- Axogen, Inc. to Participate in the 24th Annual Morgan Stanley Global Healthcare Conference
- Truist initiated coverage on AxoGen with a new price target
- EVP & General Counsel Began Marc A exercised 67,500 shares at a strike of $8.16 and sold $3,195,788 worth of shares (67,500 units at $47.34) as part of a pre-agreed trading plan (SEC Form 4)
- Director Wendell Amy Mcbride exercised 13,353 shares at a strike of $14.85 and sold $646,592 worth of shares (13,353 units at $48.42) as part of a pre-agreed trading plan (SEC Form 4)
Latest ELMD
- Electromed, Inc. to Participate in the H.C. Wainwright 28th Annual Global Investment Conference and LD Micro 20th Annual Main Event
- SEC Form 4 filed by Electromed Inc.
- SEC Form 4 filed by Electromed Inc.
- Electromed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 10-K filed by Electromed Inc.
- Electromed Announces CEO’s Planned Retirement
- Electromed, Inc. Announces Record Fiscal 2026 Fourth Quarter and Full Year Financial Results
- Electromed, Inc. to Report Q4 Fiscal 2026 Financial Results on August 25, 2026
- Chief Financial Officer Nagel Bradley M. covered exercise/tax liability with 674 shares, decreasing direct ownership by 3% to 18,964 units (SEC Form 4) (for tax liability)
- CEO and President Cunniff James L. exercised 9,700 shares at a strike of $17.25 and sold $354,095 worth of shares (9,700 units at $36.50) (SEC Form 4)